07:08 AM EDT, 07/10/2025 (MT Newswires) -- BeOne Medicines ( ONC ) said Thursday the European Commission approved Tevimbra in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma not amenable to curative surgery or radiotherapy.

The company said the indication is based on results of a study that showed a "statistically significant" improvement in progression-free survival.